Chief Executive Officer Chris Viehbacher said the drugmaker cut prices for its best-selling product, Lantus, last quarter to get on U.S. drug benefit managers' reimbursement lists in the face of competition from companies including Novo Nordisk…
Lantus has become the “next Advair” wrt pushback from payers.
*Trading lower in European home market.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”